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ORIGINAL CONTRIBUTIONPharmacokinetic Drug-Drug Interactions of Mood Stabilizers
and Risperidone in Patients Under Combined TreatmentGeorgios Schoretsanitis, MD,*† Ekkehard Haen, MD, PhD,‡ Gerhard Gründer, MD,*
Benedikt Stegmann, PhD,‡ Koen R.J. Schruers, MD, PhD,§ Christoph Hiemke, PhD,||
Sarah E. Lammertz, PhD,* and Michael Paulzen, MD*Background: The combination of anticonvulsant mood stabilizers with
antipsychotic drugs may lead to clinically relevant drug-drug interactions.
The objective of the study was to identify pharmacokinetic interactions
of different mood stabilizers on the metabolism of risperidone (RIS) under
natural conditions.
Methods: A large therapeutic drug monitoring database containing plasma
concentrations of RIS and its metabolite 9-hydroxy-RIS (9-OH-RIS) of 1,584
adult patients was analyzed. Four groups (n = 1,072) were compared: a
control group without a potentially cytochrome interacting comedication
(R0, n = 852), a group comedicated with valproate (VPA) (RVPA, n = 153),
a group comedicated with lamotrigine (LMT) (RLMT, n = 46), and a group
under concomitant medication with carbamazepine (CBZ) (RCBZ, n = 21).
Dose-adjusted plasma concentrations (C/D ratio) for RIS, 9-OH-RIS and active
moiety (AM) (RIS + 9-OH-RIS), as well as metabolic ratios (RIS/9-OH-RIS)
were computed.
Results: Groups did not differ with regard to the daily dosage (P = 0.46).
Differences were detected for the distributions of the C/D ratios for RIS,
9-OH-RIS andAM (P = 0.003,P < 0.001 andP < 0.001, respectively). Dif-
ferences remained significant after conducting a Bonferroni correction
(P = 0.0125). Pairwise comparisons of the concomitant medication groups
with the control group revealed significant differences; RIS C/D ratios were
significantly higher in the VPA and the LMT group than in the control group
(P = 0.013;P = 0.021). However, these differences did not remain significant
after Bonferroni correction. In contrast, CBZ-treated patients showed lower
dose-adjusted plasma concentrations of 9-OH-RIS (P < 0.001) as well as
the AM (P < 0.001) than the control group; this difference survived the
Bonferroni correction.
Conclusions: The data give evidence for pharmacokinetic interactions
betweenRIS and different anticonvulsantmood stabilizers. Carbamazepine
decreased serum concentrations of 9-OH-RIS and the AMwhen compared
with the control group. In case of VPA and LMT, findings were less signif-
icant; hints for a weak RIS metabolism inhibition by LMTof unclear clin-
ical significance were found.
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Journal of Clinical Psychopharmacology • Volume 36, Number 6, DecemG uidelines worldwide recommend the coadministration ofsecond-generation antipsychotics as augmentative therapy
to mood stabilizers or vice versa in the treatment of bipolar disor-
ders, especially for the treatment of manic episodes.1–3 Accep-
tance of this strategy which promises better efficacy4 despite a
higher potential of adverse events5,6 is reflected in increasing pre-
scription trends.7 Many pharmacokinetic drug-drug interactions
(DDIs) have been identified by therapeutic drug monitoring
(TDM) as TDM databases enable evaluation of pharmacokinetic
DDIs in a representative population to get an insight into the safety
and tolerability of combined psychopharmacological treatment.
Pharmacokinetic interactions in phase 1 drug metabolism, such
as inhibition or induction of cytochrome P450 (CYP) activity,
are the most important mechanisms of clinical DDIs. Combined
pharmacotherapy can lead to desired effects, attenuated effects,
and undesired harmful effects or even to serious adverse reactions.
Even in complex clinical cases, valid interaction checks are still
difficult, especially regarding the clinical relevance of a potential
interaction risk.8 Most of the psychotropic drugs are metabolized
extensively via CYP enzymes9 just like certain nonpsychiatric
drugs, such as quinidine, terbinafine, or amiodarone, which are
classified as strong, moderate or weak inhibitors of CYP2D6 ac-
cording to the Food andDrugAdministration (FDA) classification
of in vivo inhibitors of CYP2D6, whereas no inducer of CYP2D6
has been identified.10 On the other hand, several CYP3A4 inhib-
itors (eg, clarithromycin, ketoconazole, and others) as well as in-
ducers (eg, rifampin or carbamazepine [CBZ]) have been
identified.10 In recent times, the appreciation for CYP-mediated
DDI and the understanding of pharmacokinetic DDI has in-
creased, and several tables of drugs as substrates, inhibitors, and
inducers of drug-metabolizing CYP enzymes have been pub-
lished.10,11 To understand the clinical relevance of DDIs for ad-
verse drug reactions, the concept of a therapeutic window is
important.12 Based on TDM ranges, risperidone (RIS) may be a
narrow therapeutic window drug which—after adding an inhibitor
or discontinuing an inducer—may be particularly prone to cause
adverse drug reactions.13 However, any assessment regarding the
magnitude of DDIs remains uncertain with regard to the great
amount of never or scantily investigated drugs that might be cyto-
chrome blockers or inducers.
Risperidone is a second-generation antipsychotic with antago-
nistic properties at serotonin 5-HT2 and dopamine-D2 receptors.
14
Risperidone has been used effectively in the treatment of schizo-
phrenia and a broad spectrum of other psychiatric diseases.15 Ris-
peridone is mainly metabolized via CYP2D6, and the main active
metabolite is 9-hydroxy-RIS (9-OH-RIS, paliperidone). The so-
called metabolic ratio (RIS/9-OH-RIS) can be used as a CYP2D6
phenotyping index16 that is influenced by CYP2D6 polymorphism
and CYP2D6 inhibitors.17 A ratio above 1 (RIS/9-OH-RIS) > 1) is
an index of poor CYP2D6metabolism.18 Differences in 5-HT2A/D2
binding ratios and the presence of a hydroxyl-group in the 9-OH-
RIS molecule increasing hydrophilicity might explain slightly dif-
ferential pharmacological effects between 9-OH-RIS and the parent
compound.19 In vitro findings have revealed that CYP3A4 andber 2016 www.psychopharmacology.com 1
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possibly of 9-OH-RIS, a finding that was confirmed in clinical settings
using powerful inducers and inhibitors of CYP3A showing decreased
plasma concentrations of both, RIS and 9-OH-RIS, when CBZ was
added.23,24 Clinicians consider the combined concentration of
RIS + 9-OH-RIS (active moiety [AM]) as the most relevant measure
and according to the Arbeitsgemeinschaft für Neuropharmakologie
und Pharmakopsychiatrie consensus guidelines, a therapeutic ref-
erence range is suggested as 20 to 60 ng/mL for the AM.11
Valproate (VPA) is an anticonvulsant drug that has been es-
tablished as a mood stabilizer with pronounced antimanic effects
as well as an antiaggressive agent.25,26 Its major metabolic path-
ways comprise, among others, an autoinductive β-oxidation and
glucuronidation.27 Additionally, VPA is a substrate of CYP2C9
and CYP2C1928 and exerts a possible inhibitory effect on several
enzyme systems including CYP2C9, CYP2C19, and uridine
5-diphospho-glucuronosyltransferase (UGT),29,30 whereas poten-
tial inhibitory effects on CYP3A4 seem to be without clinical
significance so far. However, the mechanism and the clinical sig-
nificance of possible interactions have not been fully elucidated
and different pharmacokinetic effects on concomitantly applied
have been shown, for example, acting simultaneously as an inhib-
itor but also as an inducer of clozapine and olanzapine metabo-
lism.31 A recent study indicates that VPA might inhibit 9-OH-
RIS (paliperidone) metabolism increasing its oral bioavailability.32
Carbamazepine is frequently prescribed as a mood stabilizer
or for mood and aggression control in patients with bipolar disor-
ders and schizophrenia spectrum disorders.33 Carbamazepine is
metabolized by CYP3A4/5 and CYP2C8, whereas some data im-
ply the involvement of UGTs as well.34,35 Its primary metabolite,
CBZ 10,11-epoxide, possesses anticonvulsant activity similar to
the parent compound. There has been considerable evidence re-
garding the pharmacokinetic profile of CBZ and especially its
DDI with other antiepileptic drugs, illustrating a major inducing ef-
fect of CBZ on CYP3A4 as well as similar effects on activities of
other CYP isoenzymes, including CYP2A6, CYP2C9, CYP2C19,
CYP2B6, CYP1A2, UGTs, and P-glycoprotein.31,36,37 Moreover,
Yatham and colleagues38 detected 40% lower plasma concentra-
tions of RIS AM values in CBZ-treated patients compared with pa-
tients receiving RIS and VPA or lithium. These findings are in
agreement with data from a small clinical sample reporting a
CYP3A4-mediated interaction between CBZ and RIS, leading to
decreased plasma levels of the parent compound RIS.39 Hence,
due to its complex pharmacokinetics, CBZ can substantially affect
the disposition of a variety of psychotropic agents.
Lamotrigine (LMT) is an antiepileptic drug that is recom-
mended in bipolar disorder maintenance when depression is
prominent.40 Clinical data support its adjunctive prescription
in managing treatment-resistant positive symptoms in schizo-
phrenic patients.41 Lamotrigine is metabolized primarily by
glucuronidation.42 Uridine-diphosphate-glucuronosyltransferase
1A4 (UGT1A4) catalyzes 90% of LMT conjugation and the
major metabolite, LMT-2-N-glucuronide, is excreted via the
kidneys.43 Lamotrigine is known to induce its own metabolism
(via UGT1A4), but so far there is no evidence that LMT interacts
with drugs that are metabolized via the CYP enzyme system.
The aim of the study was to investigate whether VPA or CBZ
have the potential to interact with the CYP2D6 or CYP3A4 medi-
ated RIS metabolism reflected in changes of plasma concentrations
of RIS; its active metabolite 9-OH-RIS or the AM, RIS + 9-OH-
RIS. Furthermore, we were interested in a potential interaction be-
tween LMT and RIS because this interaction has been described
to occur with increasing plasma concentrations of RIS and 9-OH-
RIS, though an explanation for this effect is thus far lacking.442 www.psychopharmacology.comMATERIALS AND METHODS
The study was conducted as a cooperation between the De-
partment of Psychiatry, Psychotherapy, and Psychosomatics of
RWTH Aachen University Hospital, Germany, and the Depart-
ment of Psychiatry andPsychotherapy at theUniversity ofRegensburg,
Germany. Konzentrationsbestimmung von Psychopharmaka, a
large TDM database45,46 containing thousands of plasma concen-
trations of RIS and 9-OH-RIS was the source of our data. The
TDM databases are a valuable source to promote the safety and
tolerability of pharmacotherapy in a clinical setting.47,48 In the
case of multiple available plasma concentrations for 1 single pa-
tient, only the most recent value was included in the analysis. Af-
ter adjusting the database for multiple values, and after excluding
patients with depot formulations, RIS and 9-OH-RIS plasma con-
centrations were available for 1,584 adult inpatients and outpa-
tients who had been treated with RIS for different reasons. Data
collection took place between 2006 and 2015 as part of the clinical
routine in different institutions as part of the Arbeitsgemeinschaft
Arzneimittelsicherheit bei psychischen Erkrankungen, a coopera-
tion for drug safety in the treatment of psychiatric diseases (for de-
tails, www.amuep-agate.de). Retrospective analysis of clinical data
for this study was in accordance with the local regulatory authority.
We considered 4 groups; a group of patients receiving RIS as
an oral formulation (control group, R0), a group comedicated with
VPA (RVPA), a group comedicated with LMT (RLMT), and a group
with CBZ (RCBZ). No matching processes for age, diagnoses, se-
verity of illness, length, or onset of illness were undertaken. The
control group consists of patients without a comedication with
CYP2D6 or CYP3A4 inhibitory or CYP3A4 inducing properties
according to current knowledge.10,11
Quantification of RIS and 9-OH-RIS
Blood was drawn just before drug administration (trough con-
centration) at steady state (>5 elimination half-lives under the same
drug dose). Risperidone and 9-OH-RIS concentrations were deter-
mined by high performance liquid chromatography (HPLC) with
ultraviolet (HPLC/UV) detection (HPLC/UV).49,50 TheUVabsorp-
tion wavelength was set to 235 nm for quantification. The Dionex
DAD detector allowed simultaneous documentation of a second
signal at 280 nm, which was used to double-check the purity of
the signal at 235 nm. The method was validated according to
DIN 32645 (Deutsche Industrie Norm 32645, described in guide-
lines of GTFCh (Society of Toxicology and Forensic Chemistry)
in consideration of International Organization for Standardization
5725,51 US FDA guidelines,52 and International Conference on
Harmonization requirements.53 The laboratory regularly runs in-
ternal quality controls and participates in external quality assess-
ment schemes by INSTAND (Düsseldorf, Germany, www.
instandev.de). The limit of detection, defined as signal to noise ratio
of 3:1, was 5 ng/mL for both RIS and 9-OH-RIS. The interday pre-
cision, determined as duplicates on 3 different days at 5 ng/mL was
5.56 % of mean and 5.21 % of mean, respectively. Usually, twice
the limit of detection is accepted as limit of quantification. How-
ever, the analytical process using HPLC with UV (HPLC/UV) de-
tection also detects both RIS and 9-OH-RIS values below the limit
of quantification, and we decided to include these defined values
into our analysis because they were true values above 0.
Statistical Analysis
Medians and the distributions of the plasma concentrations
of RIS, 9-OH-RIS, and the AM (RIS + 9-OH-RIS) were com-
pared. Furthermore, we compared the ratio of RIS/9-OH-RIS, a
parameter that has been demonstrated to be an excellent measure
of the CYP2D6 activity.16,54 We also calculated the dose-adjusted© 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Patients' Demographic Characteristics
Group Number Age, y
Sex DD RIS, mg/d
% Females % Males Median (Range)
Valproate (RVPA) 153 41.7 (18–83) 44.4 55.6 4.0 (1.00–10.0)
Lamotrigine (RLMT) 46 46.5 (20–72) 60.9 39.1 4.0 (1.0–10.0)
Carbamazepine (RCBZ) 21 49.85 (23–83) 71.4 28.6 6.0 (1.0–9.0)
Control (R0) 852 41.25 (18–87) 44.2 55.8 4.0 (1.00–10.0)
DD indicates daily dose.
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(RIS + 9-OH-RIS), as the ratio of the plasma concentration of
RIS, 9-OH-RIS or RIS + 9-OH-RIS divided by the daily dose of
RIS (in [(ng/mL)/mg]). As the data were not normally distributed,
a nonparametrical Kruskal-Wallis test and a median test, both with
a significance level of 0.05, were conducted. For each comparison
of the 3 comedicated groups (RVPA, RLMT, RCBZ) with the control
group (R0), we used the Mann-Whitney U test with the same sig-
nificance level. Furthermore, we conducted a Bonferroni correc-
tion, setting a significance cutoff at 0.0125. Statistical analysis
was carried out using IBM SPSS Statistics version 18.0 (IBM
GmbH, Ehningen, Germany).RESULTS
One thousand seventy-two of 1,584 patients were eligible for
analysis (no other confounding comedication according to the
FDA classification of in vivo inhibitors of CYP enzymes10) and
were assigned to the 4 groups, R0 (n = 852), RVPA (n = 153), RLMT
(n = 46), and RCBZ (n = 21). The demographic data of these pa-
tients are summarized in Table 1.
The median plasma concentrations (ng/mL) of RIS, 9-OH-
RIS, the AM (RIS + 9-OH-RIS), as well as the metabolic ratios
(RIS/9-OH-RIS) are displayed in Table 2 and in Fig. 1.
Table 3 shows the C/D ([ng/mL]/mg) for RIS, 9-OH-RIS,
and RIS + 9-OH-RIS.
Because of the skewness of the distribution, comparisons
were based upon the Kruskal-Wallis test. No differences were
found regarding the distribution and the medians of daily dosage
of RIS between the groups (P = 0.46 and P = 0.086) (R0: mean,
4.34 mg/d; SD, 2.03; RVPA: mean, 4.43 mg/d; SD, 2.21; RLMT:
mean, 4.51 mg/d; SD, 2.19; and RCBZ: mean, 5.07 mg/d; SD,
2.44). The comparison of the distribution (subscript indices ‘D’)TABLE 2. Median (and Range) Plasma Concentrations and Metabo
Group RIS, ng/mL 9-OH-RIS, ng/m
Valproate (RVPA) 7.0*(0.1–252.0) 16.0 (1.2–147.
Lamotrigine (RLMT) 6.4
† (0.2–60.9) 15.5 (2.0–83.5
Carbamazepine (RCBZ) 4.0 (0.2–42.0) 9.6
‡ (1.9–55.0
Control (R0) 4.4 (0.1–224.0) 17.0 (0.3–196.
*Plasma concentration values for RIS and metabolic ratios in the RVPA grou
P = 0.016 and P = 0.017 for Mann-Whitney U Test).
†Plasma concentration values for RIS and metabolic ratios in the RLMT grou
P = 0.016 and P = 0.004 for Mann-Whitney U Test).
‡Plasma concentration values for 9-OH-RIS and RIS + 9-OH-RIS in the R
P = 0.001 and P = 0.001 for Mann-Whitney U Test).
© 2016 Wolters Kluwer Health, Inc. All rights reserved.and the medians (subscript indices ‘M’) of the plasma concentra-
tions of RIS, 9-OH-RIS, and the AM (RIS + 9-OH-RIS) between
the 4 groups yielded significant differences in all cases (RISD,
P = 0.006; 9-0H-RISD, P = 0.008; and RIS + 9-OH-RISD,
P = 0.004; RISM, P = 0.021; 9-0H-RISM, P = 0.012 and RIS + 9-
OH-RISM, P = 0.002). Similarly, the distributions of the dose-
adjusted plasma concentrations, C/D ratios, showed significant
differences between the groups (RISD C/D ratio, P = 0.003;
9-OH-RISD C/D ratio, P < 0.001; and RIS + 9-OH-RISD C/D ra-
tio, P < 0.001). When comparing medians of these parameters, we
detected significant differences between the groups for 9-OH-RIS
C/D and RIS + 9-OH-RIS C/D but not for RIS C/D (9-OH-RISM
C/D ratio, P < 0.001; RIS + 9-OH-RISM C/D ratio, P = 0.002;
RISD C/D ratio, P = 0.108). Significant differences were also de-
tected between the distributions, but not the medians of RIS/9-
OH-RIS ratios of 4 groups (P = 0.004 and P = 0.051).
To eliminate type 1 errors, we chose to apply a Bonferroni
correction adjusting our initial P value and setting a cutoff of
0.0125. Differences between the distributions and the medians re-
mained significant with the exception of the differences between
median plasma concentrations of RIS (Fig. 2).
To control for significant differences between pairs of groups
(R0 vs RVPA, R0 vs RLMT, and R0 vs RCBZ), a Mann-Whitney U
test was used. Patients that were comedicated with VPA showed
significantly higher plasma concentrations and a higher RIS
C/D ratio compared with the control group (P = 0.016 and
P = 0.013), whereas plasma concentrations and 9-OH-RIS C/D
ratio (P = 0.869 and P = 0.585) as well as plasma concentra-
tions and RIS + 9-OH-RIS C/D ratio (P = 0.221 and P = 0.111)
showed no significant differences. However, the metabolic ratios
(RIS/9-OH-RIS) were significantly different, with higher values
in the VPA group (P = 0.017). After applying the Bonferroni cor-
rection, none of the differences remained significant.lic Ratios of Risperidone in the Study Groups
L RIS + 9-OH-RIS, ng/mL RIS/9-OH-RIS
0) 27.0 (1.7–255.7) 0.363*(0.009–68.1)
) 23.5 (8.0–144.4) 0.525† (0.008–27.0)
) 14.8‡ (3.3–57.9) 0.333 (0.052–5.25)
5) 24.0 (1.8–264.0) 0.262 (0.003–23.68)
p were significantly higher compared with the control group (uncorrected
p were significantly higher compared with the control group (uncorrected
CBZ group were significantly lower than in the control group (uncorrected
www.psychopharmacology.com 3
FIGURE 1. Median plasma concentrations of RIS, 9-OH-RIS and active moiety as well as the metabolic ratios (RIS/9-OH-RIS) in the 4 different
study groups. RLMT = lamotriginegroup; RVPA = valproate group; RCBZ = carbamazepine group; R0 = control group. CI = confidence interval.
C/D for RIS, 9-OH-RIS and RIS + 9-OH-RIS in [(ng/ml)/mg]. Metabolic ratio (RIS/9-OH-RIS) without unit.
Schoretsanitis et al Journal of Clinical Psychopharmacology • Volume 36, Number 6, December 2016The Mann-Whitney U test revealed similar patterns of distri-
bution differences when comparing the LMT group versus the
control group. Plasma concentrations and dose-adjusted plasma
concentrations of the parent compound, RIS, differed between the
groups, with LMT patients showing higher values (P = 0.016 and
P = 0.021). Differences failed to reach significance levels in case
of the AM (P = 0.732 for RIS + 9-OH-RIS and P = 0.745 for
RIS + 9-OH-RISC/D ratio) as well as in the case of active metabolite
(P = 0.552 for 9-OH-RIS and P = 0.182 for 9-OH-RIS C/D ratio).
Metabolic ratio (RIS/9-OH-RIS) values were higher in the LMT
group (P = 0.004) and remained significant after the Bonferroni cor-
rection, whereas the others did not.
The coadministration of CBZ led to completely different
findings. Comparing the CBZ versus the control group yielded
no significant differences regarding RIS (P = 0.29 for RIS and
P = 0.096 for RIS C/D ratio), and the metabolic ratios did not dif-
fer between the 2 groups (P = 0.253). However, both the plasma
concentration of the active metabolite as well as the AMwere sig-
nificantly lower in the CBZ group (P = 0.001 for 9-OH-RIS and
P < 0.001 for 9-OH-RIS C/D ratio, P = 0.001 for RIS + 9-OH-
RIS, and P < 0.001 for RIS + 9-OH-RIS C/D ratio). The
Bonferroni correction did not change results as all differences
remained significant.
Further analysis included the distribution pattern, C/D and
metabolic ratios for the study groups. In the CBZ group, only
1 patient had a 9-OH-RIS C/D ratio higher than the median,
whereas the rest of the group (n = 20) showed a 9-OH-RIS C/D
ratio below the median. Similarly striking are the findings regard-
ing the AM C/D ratios, with 2 patients in the CBZ group showing
RIS + 9-OH-RIS C/D values above the median. AlthoughTABLE 3. Median C/D of Risperidone in the Different Groups
Group RIS C/D ratio [(ng/ml)/mg] 9-OH-RIS C
Valproate (RVPA) 1.77* (0.03–63.0) 4.00
Lamotrigine (RLMT) 1.5
† (0.03–27.0) 3.83
Carbamazepine (RCBZ) 0.66 (0.13–10.5) 2.00
‡
Control (R0) 1.16 (0.02–74.67) 4.33
*C/D values for RIS in the RVPA-group were significantly higher than in the
†C/D values for RIS in the RLMT group were significantly higher than in the
‡C/D values for 9-OH-RIS and RIS + 9-OH-RIS in the RCBZ group were
P < 0.001 for Mann-Whitney U test).
4 www.psychopharmacology.comconsidering this distribution pattern differences, it should be kept
in mind that the median 9-OH-RIS and AM C/D ratios were sig-
nificantly lower in the CBZ group compared with all 3 groups
(P < 0.001 and P = 0.002). Considering the distribution of the
RIS C/D values of the 4 groups, patients with a coadministration
of CBZ tend to show median values below the median, whereas
in the 2 other groups and in the control group, the distributions
were more balanced.
Considering the effects of the other 2 investigated mood sta-
bilizers (VPA and LMT), findings reached statistical significance
regarding RIS plasma concentrations and C/D values, but were
not substantially reflected in differences in the AM (RVPA vs R0:
P = 0.221 for RIS + 9-OH-RIS and P = 0.111 for RIS + 9-OH-
RIS C/D ratio; RLMT vs R0: P = 0.732 for RIS + 9-OH-RIS and
P = 0.745 for RIS + 9-OH-RIS C/D ratio).DISCUSSION
The augmentation of an antipsychotic pharmacotherapy with
an anticonvulsant as a mood stabilizer is a very common psycho-
pharmacological practice. However, by adding an anticonvulsant
to an ongoing antipsychotic treatment, the risk of pharmacokinetic
DDIs is increasing. For predicting potential DDIs, knowledge
about pharmacokinetic interactions, predominantly involving the
CYP system, is of high value. For a better understanding of poten-
tially occurring DDIs in complex multiple drug therapy settings,
data from TDM surveys are an ideal source for identification
and quantification of risks.55,56
In our naturalistic sample, patients on a stable dose with RIS
in the control group and patients that were comedicated with VPA,/D ratio [(ng/ml)/mg] RIS + 9-OH-RIS C/D ratio [(ng/ml)/mg]
(0.27–23.33) 6.66 (0.38–63.93)
(0.31–27.83) 6.02 (1.3–48.13)
(0.48–6.88) 2.62‡ (1.7–12.5)
(0.08–42.0) 6.29 (0.5–88.0)
control group (uncorrected P = 0.013, for Mann-Whitney U test).
control group (uncorrected P = 0.021 for Mann-Whitney U test).
significantly lower than in the control group (uncorrected P < 0.001 and
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Median dose-adjusted plasma concentrations (C/D) for risperidone, 9-hydroxyrisperidone and active moiety in the different
groups. RLMT = lamotrigine group; RVPA = valproate group; RCBZ = carbamazepine group; R0 = control group. C/D for RIS, 9-OH-RIS and
RIS + 9-OH-RIS in [(ng/ml)/mg].
Journal of Clinical Psychopharmacology • Volume 36, Number 6, December 2016 Risperidone Combined With Mood StabilizersLMT, or CBZ showed considerably different patterns of plasma
concentrations of RIS, 9-OH-RIS, and AM as well as different
patterns of dose-adjusted plasma concentrations (C/D).
The most impressive findings were seen in the CBZ group.
Both the median plasma concentration and the dose-adjusted
plasma concentration of 9-OH-RIS and AM were about 2-fold
lower than in the control group, revealing results that are in line
with correction factors for potent inducers, such as CBZ, as sug-
gested by de Leon et al.4,31 The comparison of the plasma and
the dose-adjusted plasma concentrations of RIS between the
CBZ and the control group did not yield statistically significant
differences. However, the numeric difference has to be taken into
account, that is, in case of RIS C/D ratio, the median value for
CBZ patients was 0.66 (ng/mL)/mg, whereas it was 1.16 (ng/
mL)/mg in the control group. Significantly lower concentrations
might be due to an induction of the cytochrome mediated metab-
olism of RIS. Nonetheless, the inducing properties of CBZ are
rather unlikely to be attributed to an enhanced 9-hydroxylation
of RIS via CYP2D6 but might be the result of an induction of alter-
native metabolic pathways, such as the CYP3A4-mediated metabo-
lism of RIS. Given that the plasma concentration of RIS did not
show significant differences between the CBZ and the control
group (P = 0.383 for RIS andP = 0.165 for RISC/D ratio), wewere
able to rule out the possibility that this prominent decrease may
somehow be due to differences of plasma concentration of RIS.
Although the daily dose of RIS was not significantly different
between the study groups, significantly lower plasma concentrations
of 9-OH-RIS in the CBZ group contributed to a substantially lower
concentration of the AM with potential clinical implications
(P = 0.001 for RIS + 9-OH-RIS and P < 0.001 for RIS + 9-OH-
RIS C/D ratio), although we did not analyze clinical features due to
our pharmacokinetic approach. Differences between patients that
were comedicatedwithCBZ and those in the control-group remained
significant after conducting a Bonferroni correction. Our observation
is in accordance with previous small clinical studies and case reports
that indicated an inducing effect of CBZ on the RIS metabo-
lism.23,38,39,57 The clinical relevance of the alterations in RIS metab-
olism attributed to CBZ has been demonstrated by case reports, for
example, an acute psychotic exacerbation after prescribing CBZ in
a patient under RIS58 or the appearance of extrapyramidal symptoms
(EPS) after withdrawing CBZ from the therapeutic regimen.59
Consequently, individualization of the doses or better the ther-
apeutic plasma concentrations of antipsychotics, such as RIS, using
TDM should be considered to maintain a favorable antipsychotic© 2016 Wolters Kluwer Health, Inc. All rights reserved.effect when CBZ is coadministered, or to avoid adverse reactions
when a CYP-inducing comedication is stopped.60,61 Especially in
the case of CBZ discontinuation, Punyawudho and colleagues62 es-
timated that enzyme induction should be reduced by about half after
3 days of discontinuation, by 75% after 7 days and a return to a nor-
mal status might be achieved after 2 weeks.
In terms of VPA, in vitro findings may be explained by
inhibiting properties on CYP3A4,29 which is further supported
by in vivo findings that showed inhibiting effects of VPA on the
metabolism of quetiapine, a CYP3A4 substrate.63 Aweak inhibi-
tion of the CYP3A4-mediated metabolism of RIS offers a plausi-
ble interpretation of our findings although the findings did not
survive Bonferroni correction.
With regard to possible pharmacokinetic interactions between
RIS and LMT, data are lacking so far. In our study, the RIS/9-OH-
RIS ratio in the LMT group was significantly higher, and although
statistical significance of higher serum concentrations of the parent
compound RIS did not survive Bonferroni correction, the RIS/9-
OH-RIS ratio remained significant. A higher RIS/9-OH-RIS ratio
in patients who are comedicated with LMT might be considered
as a hint for aweak inhibiting effect on the CYP 3A4-mediated me-
tabolism of RIS or for an inhibition of RIS metabolism that might
not be limited to phase 1 metabolism. Only 1 single case report
demonstrated enhanced RIS plasma concentrations after a concom-
itant therapy with LMT,44 whereas findings from a small clinical
sample did not report changes in RIS concentrations after coadmin-
istration of LMT.64 Literature data suggest UGT-mediated interac-
tions of LMTwith other psychotropic agents.64,65 Hence, it should
be pointed out that a possible weak inhibitory effect of LMT on
RIS metabolism—mediated by either cytochrome or UGT—might
explain our findings but is unlikely to be of clinical significance.
Summarizing the findings, CYP3A4 seems to play a sub-
stantial role in the metabolism of RIS, consistent with in vitro
findings that have illustrated an involvement of CYP3A4 in the
metabolism of RIS. In the light of our findings any additionally
prescribed comedication to an ongoing RIS treatment has to be
critically evaluated regarding CYP2D6 inhibiting and/or CYP3A4
inhibiting or inducing properties. In case of CBZ, another ex-
planation of the interaction pharmacology may be seen in its
P-glycoprotein inducing properties, while RIS is a substrate of P-gp.
So the combination of CBZ and RIS could lead to lower plasma
concentrations of RIS and 9-OH-RIS as a consequence of a reduced
absorption from the gastrointestinal tract.37 Regarding the interac-
tion of VPA and LMTwith RIS, findings were less clear with onlywww.psychopharmacology.com 5
Schoretsanitis et al Journal of Clinical Psychopharmacology • Volume 36, Number 6, December 2016a higher RIS/9-OH-RIS ratio for LMT surviving the adjustment of
the significance cutoff. This might imply a mild inhibitory effect of
LMT on RIS metabolism that clinicians should be aware of.
Limitations
Our sample comprised a large population of naturalistic ob-
servations and relies on retrospective data. A significant amount
of clinical parameters (onset and duration of illness, adverse ef-
fects, comorbidities, duration of drug exposure) were not avail-
able. Furthermore, we could not control for potentially large
individual variations in sampling time (although clinicians were
asked to draw blood at trough level times) as a result of the clinical
setting. This may have contributed to the pronounced interindivid-
ual variation in plasma concentrations and metabolic ratios. Other
important limitations can be seen in the lack of information about
CYP2D6 genotypes (PMs around 7% of the sample) and lack of
information on renal insufficiency as 9-OH-RIS is mainly elimi-
nated via the kidneys. Independent of differences in clinical rou-
tine, a large interindividual variability in RIS and 9-OH-RIS
concentrations has already been reported in the literature.66 In
the case of multiple plasma concentration determinations, wemin-
imized the patient bias by including only the most recent analysis
per patient. Regarding the analyses of the data, we observed differ-
ences in sample characteristics and sample size in the 4 patient
groups; thus, the comparability of the study groups with the con-
trol group might be restricted.
Consequently, we avoided stratifying for age and sex despite
the previously reported effect of both on RIS metabolism to evade
perplexing our analysis.17,67 We chose not to reduce the control
group taking into account the extent of the skewness of the sample
distribution. Finally, statistical significance is heavily influenced
by sample size, and our findings have to be considered keeping
in mind the effect sizes.
Clinical points
• The combination of mood stabilizers with antipsychotic drugs is
a common augmentation strategy but may lead to clinically rel-
evant pharmacokinetic interactions.
• Evidence is provided for pharmacokinetic interactions between
RIS and different mood stabilizers.
• CBZ provides the highest pharmacokinetic interaction potential
with RIS but also valproic acid and LMTmay lead to significant
changes in plasma concentrations of RIS, its active metabolite
and the AM.
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